Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,437 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,348)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05353205 | A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. | unknown | Phase 4 | 200 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 29, 2022 | clinicaltrials |
| NCT05340985 | Investigating the Effects of Hydroxyvitamin D3 on Multiple Sclerosis | unknown | Phase 4 | 54 | Tehran University of Medical SciencesOTHER | 0 | Apr 22, 2022 | clinicaltrials |
| NCT04677439 | Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure | unknown | Phase 4 | 200 | Shenzhen Second People's HospitalOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT01358201 | PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years | unknown | Phase 4 | 100 | PETHEMA FoundationOTHER | 1 | Jan 19, 2022 | clinicaltrials |
| NCT01366898 | Protocol For the Treatment Acute Lymphoblastic Leukemia With Ph 'Negative in Elderly Patients (> 55 Years) | unknown | Phase 4 | 100 | PETHEMA FoundationOTHER | 1 | Jan 19, 2022 | clinicaltrials |
| NCT05137860 | Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD | unknown | Phase 4 | 56 | Hospital General de MexicoOTHER_GOV | 1 | Jan 18, 2022 | clinicaltrials |
| NCT05133310 | Effect of Simvastatin on Sepsis and Febrile Neutropenia in Patients With Acute Lymphoblastic Leukemia | unknown | Phase 4 | 108 | Hospital General de MexicoOTHER_GOV | 1 | Jan 4, 2022 | clinicaltrials |
| NCT05176119 | Nalbuphine Versus Ketamine for Prevention of Emergence Agitation After Sevoflurane in Children Undergoing Tonsillectomy | completed | Phase 4 | 90 | Ain Shams UniversityOTHER | 1 | Jan 4, 2022 | clinicaltrials |
| NCT01191541 | Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL)(Ara-C) | completed | Phase 4 | 65 | Xiaofan ZhuUNKNOWN | 1 | Aug 10, 2021 | clinicaltrials |
| NCT00980018 | An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment(MACS0999) | completed | Phase 4 | 52 | Novartis PharmaceuticalsINDUSTRY | 2 | Jul 1, 2021 | clinicaltrials |
| NCT01131325 | Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations(MACS1148) | terminated | Phase 4 | 3 | Novartis PharmaceuticalsINDUSTRY | 1 | May 20, 2021 | clinicaltrials |
| NCT04636918 | Ikervis for DED Due to GVHD Post Allo-HSCT(Ikervis) | unknown | Phase 4 | 40 | Singapore Eye Research InstituteOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT03176849 | A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT | completed | Phase 4 | 49 | Phoenix Children's HospitalOTHER | 1 | Nov 17, 2020 | clinicaltrials |
| NCT01856803 | Anti-thymocyte Globulins for Graft-versus-host Disease Prophylaxis | completed | Phase 4 | 300 | Peking University People's HospitalOTHER | 1 | Sep 25, 2020 | clinicaltrials |
| NCT00853008 | Treatment of High Risk Adult Acute Lymphoblastic Leukemia(LAL-AR/2003) | completed | Phase 4 | 100 | PETHEMA FoundationOTHER | 1 | Apr 7, 2020 | clinicaltrials |
| NCT02875743 | King's Invasive Aspergillosis Study II | completed | Phase 4 | 120 | King's College Hospital NHS TrustOTHER | 1 | Apr 2, 2020 | clinicaltrials |
| NCT01243489 | Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation(Crescendo) | completed | Phase 4 | 104 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbHOTHER | 1 | Dec 20, 2019 | clinicaltrials |
| NCT04187755 | Cefepime vs Ceftazidime as Empirical Therapy for Neutropenic Fever | completed | Phase 4 | 72 | Indonesia UniversityOTHER | 1 | Dec 6, 2019 | clinicaltrials |
| NCT01578213 | Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients(ISAV) | completed | Phase 4 | 112 | University of Milano BicoccaOTHER | 5 | Dec 3, 2019 | clinicaltrials |
| NCT00003398 | Bone Marrow Transplantation in Treating Patients With Hematologic Cancer | completed | Phase 4 | 45 | University of Maryland, BaltimoreOTHER | 1 | Oct 17, 2019 | clinicaltrials |
| NCT01987297 | Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL | unknown | Phase 4 | 738 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Aug 19, 2019 | clinicaltrials |
| NCT03369847 | Inhaled Steroids for Pediatric Asthma at Pediatric Emergency Medicine Discharge | completed | Phase 4 | 43 | New York City Health and Hospitals CorporationOTHER | 1 | Jul 18, 2019 | clinicaltrials |
| NCT03920813 | Determinants of Mercaptopurine Toxicity in Paediatric Acute Lymphoblastic Leukemia Maintenance Therapy | unknown | Phase 4 | 500 | Shandong UniversityOTHER | 0 | Apr 23, 2019 | clinicaltrials |
| NCT02670564 | ALL SCTped FORUM - Pharmacogenomic Study (add-on Study) | unknown | Phase 4 | 1,000 | Swiss Pediatric Oncology GroupOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT01283386 | A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status | terminated | Phase 4 | 26 | Hoffmann-La RocheINDUSTRY | 1 | Mar 14, 2019 | clinicaltrials |
| NCT02095951 | Preemptive Ethanol Lock Therapy in Pediatric Bloodstream Infection | completed | Phase 4 | 30 | Children's Hospital of MichiganOTHER | 1 | Dec 19, 2018 | clinicaltrials |
| NCT02933333 | G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor | unknown | Phase 4 | 405 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 17, 2018 | clinicaltrials |
| NCT02204722 | A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients(IDEAL) | terminated | Phase 4 | 55 | Dong-A ST Co., Ltd.INDUSTRY | 1 | Jun 15, 2018 | clinicaltrials |
| NCT01200355 | Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome | completed | Phase 4 | 113 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 7, 2018 | clinicaltrials |
| NCT01819792 | Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related Aplasia(LAMVIRE) | completed | Phase 4 | 119 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Apr 23, 2018 | clinicaltrials |
| NCT01906671 | Study on Two Different Formulations of 6-mercaptopurine. Tablet Versus Oral Liquid | unknown | Phase 4 | 16 | Kjeld SchmiegelowOTHER | 1 | Apr 20, 2018 | clinicaltrials |
| NCT01271010 | A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status | terminated | Phase 4 | 89 | Hoffmann-La RocheINDUSTRY | 1 | Mar 20, 2018 | clinicaltrials |
| NCT01347996 | Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia | completed | Phase 4 | 84 | Cytovia, Inc.OTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00666978 | Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking | completed | Phase 4 | 540 | Lisa Sanderson Cox, PhDOTHER | 1 | Nov 13, 2017 | clinicaltrials |
| NCT03332511 | Efficacy and Safety of Nilotinib in CML-CP(ENESTKorea) | completed | Phase 4 | 110 | Seoul National University HospitalOTHER | 0 | Nov 6, 2017 | clinicaltrials |
| NCT03216070 | Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia | unknown | Phase 4 | 12 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Jul 13, 2017 | clinicaltrials |
| NCT00576472 | Learning Impairments Among Survivors of Childhood Cancer | completed | Phase 4 | 469 | St. Jude Children's Research HospitalOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT03150134 | Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients | unknown | Phase 4 | 100 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 12, 2017 | clinicaltrials |
| NCT01625455 | Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome | terminated | Phase 4 | 7 | Vanderbilt University Medical CenterOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT01605981 | Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.(MACS1881) | withdrawn | Phase 4 | 0 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 20, 2017 | clinicaltrials |
| NCT00686543 | Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115) | completed | Phase 4 | 75 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 7, 2017 | clinicaltrials |
| NCT02086487 | Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy(NISRI) | terminated | Phase 4 | 98 | King Abdullah International Medical Research CenterOTHER | 1 | Mar 7, 2017 | clinicaltrials |
| NCT00361140 | Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) | completed | Phase 4 | 72 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT01206088 | Tasigna in Glivec-resistant or Intolerant Patients in CML | completed | Phase 4 | 93 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 28, 2017 | clinicaltrials |
| NCT00171899 | Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) | completed | Phase 4 | 80 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 23, 2017 | clinicaltrials |
| NCT00786812 | Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase(MACS0439) | completed | Phase 4 | 89 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 23, 2017 | clinicaltrials |
| NCT03026842 | Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21) | unknown | Phase 4 | 180 | The First Hospital of Jilin UniversityOTHER | 1 | Jan 20, 2017 | clinicaltrials |
| NCT01660906 | Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib | completed | Phase 4 | 39 | Bristol-Myers SquibbINDUSTRY | 5 | Nov 22, 2016 | clinicaltrials |
| NCT01368523 | Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial | completed | Phase 4 | 19 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 16, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Apr 29, 2022source: clinicaltrials